RET D898_E901del
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene RET
Variant D898_E901del
Impact List deletion
Protein Effect gain of function
Gene Variant Descriptions RET D898_E901del results in the deletion of four amino acids in the protein kinase domain of the Ret protein from amino acids 898 to 901 (UniProt.org). D898_E901del confers a gain of function to Ret as demonstrated by increased Erk phosphorylation (PMID: 32284345), increased Ret phosphorlyation, (PMID: 37535881), cytokine-independent growth in culture (PMID: 32284345, PMID: 37535881), and tumor formation in a mouse model (PMID: 37535881).
Associated Drug Resistance
Category Variants Paths

RET mutant RET act mut RET D898_E901del

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_020975.6
gDNA chr10:g.43120167_43120178del12
cDNA c.2694_2705del12
Protein p.D898_E901delDVYE
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001406772.1 chr10:g.43126623_43126634del12 c.2692_2703del12 p.D898_L901delDDGL RefSeq GRCh38/hg38
NM_001406743.1 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901delDVYE RefSeq GRCh38/hg38
NM_001406759.1 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901delDVYE RefSeq GRCh38/hg38
NM_001406773.1 chr10:g.43126665_43126676del12 c.2692_2703del12 p.N898_P901delNNAP RefSeq GRCh38/hg38
NM_001406769.1 chr10:g.43126623_43126634del12 c.2692_2703del12 p.D898_L901delDDGL RefSeq GRCh38/hg38
NM_001406761.1 chr10:g.43123690_43123701del12 c.2692_2703del12 p.L898_I901delLWEI RefSeq GRCh38/hg38
NM_020630.7 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901delDVYE RefSeq GRCh38/hg38
NM_001406765.1 chr10:g.43123696_43123707del12 c.2692_2703del12 p.E898_T901delEIVT RefSeq GRCh38/hg38
NM_001406770.1 chr10:g.43124923_43124934del12 c.2692_2703del12 p.K898_V901delKRPV RefSeq GRCh38/hg38
NM_001406763.1 chr10:g.43123696_43123707del12 c.2692_2703del12 p.E898_T901delEIVT RefSeq GRCh38/hg38
NM_001406762.1 chr10:g.43123690_43123701del12 c.2692_2703del12 p.L898_I901delLWEI RefSeq GRCh38/hg38
NM_001406766.1 chr10:g.43124923_43124934del12 c.2692_2703del12 p.K898_V901delKRPV RefSeq GRCh38/hg38
NM_020975.5 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901del RefSeq GRCh38/hg38
NM_001406744.1 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901delDVYE RefSeq GRCh38/hg38
NM_001406760.1 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901delDVYE RefSeq GRCh38/hg38
NM_001406767.1 chr10:g.43124923_43124934del12 c.2692_2703del12 p.K898_V901delKRPV RefSeq GRCh38/hg38
NM_001406764.1 chr10:g.43123690_43123701del12 c.2692_2703del12 p.L898_I901delLWEI RefSeq GRCh38/hg38
NM_001406771.1 chr10:g.43126665_43126676del12 c.2692_2703del12 p.N898_P901delNNAP RefSeq GRCh38/hg38
NM_001406768.1 chr10:g.43124901_43124912del12 c.2694_2705del12 p.C899_Q902delCWKQ RefSeq GRCh38/hg38
NM_020630.5 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901del RefSeq GRCh38/hg38
NM_020975.6 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901delDVYE RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RET D898_E901del Advanced Solid Tumor sensitive Selpercatinib Preclinical - Cell culture Actionable In a preclinical study, Retevmo (selpercatinib) inhibited Erk phosphorylation and growth of transformed cells expressing RET D898_E901del in culture (PMID: 32284345). 32284345
RET D898_E901del Advanced Solid Tumor sensitive Selpercatinib Preclinical - Cell culture Actionable In a preclinical study, Retevmo (selpercatinib) inhibited Ret phosphorylation and proliferation in a transformed cell line expressing RET D898_E901del in culture (PMID: 37535881). 37535881
RET D898_E901del Advanced Solid Tumor sensitive Pralsetinib Preclinical - Cell culture Actionable In a preclinical study, Gavreto (pralsetinib) inhibited Erk phosphorylation and growth of transformed cells expressing RET D898_E901del in culture (PMID: 32284345). 32284345
RET D898_E901del medullary thyroid carcinoma predicted - resistant Vandetanib Case Reports/Case Series Actionable In a clinical case study, a patient with metastatic medullary thyroid carcinoma harboring RET D898_E901del demonstrated primary resistance to Caprelsa (vandetanib) treatment (PMID: 37535881). 37535881
RET D898_E901del medullary thyroid carcinoma sensitive Selpercatinib Case Reports/Case Series Actionable In a clinical case study, Retevmo (selpercatinib) treatment resulted in a 61% reduction in the sum of the diameters of the target lesions in a patient with metastatic medullary thyroid carcinoma harboring RET D898_E901del, with treatment lasting 1 year (PMID: 37535881). 37535881
RET D898_E901del medullary thyroid carcinoma sensitive Selpercatinib FDA approved - On Companion Diagnostic Actionable In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET D898_E901del; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128). detail... detail... 32846061
RET D898_E901del medullary thyroid carcinoma sensitive Selpercatinib Case Reports/Case Series Actionable In a Phase I/II trial (LIBRETTO-001), Retevmo (selpercatinib) treatment resulted in a clinical response after one month, with a partial response in liver lesions and abdominal lymph nodes that was maintained for 24 months, in a patient with metastatic medullary thyroid carcinoma harboring RET D898_E901del (PMID: 38438731; NCT03157128). 38438731
RET D898_E901del Advanced Solid Tumor resistant Cabozantinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing RET D898_E901del were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 37535881). 37535881
RET D898_E901del Advanced Solid Tumor predicted - sensitive Vandetanib Preclinical - Cell culture Actionable In a preclinical study, Caprelsa (vandetanib) inhibited Ret phosphorylation and proliferation in a transformed cell line expressing RET D898_E901del, but to a lesser degree than cells expressing RET C634R in culture (PMID: 37535881). 37535881